



ICPM
2008
AMSTERDAM

The 15th International
Conference on Pharmaceutical
Medicine in
Amsterdam The Netherlands

ICPM 2008 secretariat

Mrs Caroline van Bruggen
Mrs Miranda Meulstee
Remdementsweg 24 E-1
3641 SL Mijdrecht
The Netherlands
phone: +31 (0)297 285144
Fax: +31 (0)297 256046

Conference organizer

TCM

Mr George Brouwer
Mr Jeroen Hof
PO Box 103

1170 AC Badhoevedorp
The Netherlands

phone: +31 (0)206597970
Fax: +31 (0) 20 6597762

www.icpm2008.org

please visit our website for
registration, information,
updates and newsletters

Venue

Okura Hotel Amsterdam
Ferdinand Bolstraat 333
1072 LH Amsterdam

phone: +31 (0)20 6787111

www.okura.nl

Hosted by



NEWSLETTER

International Conference on Pharmaceutical Medicine 2008

7 - 10 September

Developing Pharmaceutical Care

Medicines after the blockbuster era

Dear Colleagues in Pharmaceutical Medicine,

Just 10 months to go before the opening of the next edition of the International Conference on Pharmaceutical Medicine 2008 in Amsterdam! On behalf of the local organizing committee I am very pleased that the online registration form on our website: www.icpm2008.org. is in use as of November 1st 2007. On the website You'll find the latest news, the updated version of the scientific program, all the details of the call for abstracts, and information about hotels and some social activities during the conference. Turn this website into one of you're favourites during the next 10 months!

Why should you come to the ICPM2008 in Amsterdam ?

This conference is the two-yearly vaccination to improve your actual knowledge on different key-topics in pharmaceutical medicine. This conference is specifically designed to address all the aspects of pharmaceutical medicine in the current changing environment. For scientists and colleagues working in the field of clinical operations we made a very interesting parallel program which takes the overall congress theme "Developing Pharmaceutical Care; Medicines after the Blockbuster Era", as a starting point

In addition to the normal scientific program there are 3 parallel 'executive training modules' (free of charge!) during the morning session: 1. statistics for non-intervention studies, 2. update in risk management planning, 3. media training for pharma-executives. You can use the button on your online registration form to have a chance to participate in these executive classes! Because there is limited capacity, participation is depending on the order in online registration and payment.

Beside the scientific program we will organize an interesting Welcome Reception in the Rijksmuseum and an unforgetfull Dutch Gala Dinner in the Beurs of Berlage. All activities take place around the centre of Amsterdam. From now on you'll find a new ICPM2008 Newsletter each month on the website, with the latest update of our world congress on pharmaceutical medicine! Looking forward to meet you all in Amsterdam!

On behalf of local organizing and scientific committee,



Rudolf van Olden, MD, PhD
Chairperson ICPM2008

	Monday Developing Pharmaceutical Care	Tuesday Medicines after Blockbuster Era	Wednesday Pharmaceutical Future
Morning plenary program	<p>State of the Art in Translational Medicine</p> <ul style="list-style-type: none"> - Physiology based modelling - From bedside to bench - New translational models <p>State of the Art in Trial Design Technology</p> <ul style="list-style-type: none"> - Validity of biomarkers and surrogate endpoints - Pharmacogenomics in trial design - Adaptive clinical trial design: pro's and con's 	<p>Highly Specialized Indications in Research</p> <p>Paediatric research</p> <ul style="list-style-type: none"> - Essentials of paediatric drug development - Regulatory aspects of paediatric drug development - The role of paediatric networks <p>Orphan World</p> <ul style="list-style-type: none"> - Ethical issues in funding orphan research - 25 yrs orphan drug development in US - Hurdles in orphan drug development 	<p>Any end of the Blockbuster Mindset?</p> <ul style="list-style-type: none"> - R&D philosophy: private-public partnerships - Targeted therapies: nichebusters? - Drivers behind science: role of financial investor <p>From Science to Public Conscience</p> <ul style="list-style-type: none"> - Choices made by the pharmaceutical physician - Choices made by the media - Societal Responsibility Together?
Morning short course program	<p>Statistics for non-interventional studies</p> <p>Media Training, work within pharmaceutical crisis</p> <p>Update in Risk-Benefit Analyses</p>	<p>Statistics for non-interventional studies</p> <p>Media Training, work within pharmaceutical crisis</p> <p>Update in Risk-Benefit Analyses</p>	
Lunch Symposia	<p>Examples</p> <ul style="list-style-type: none"> - drug devices - generics / biosimilars - vaccins 	<p>Examples</p> <ul style="list-style-type: none"> - phase IV commitments - oncology: future of all cause mortality - therapy optimizing studies role of industry 	
Afternoon physician program	<p>Medical Research after Marketing Authorisation</p> <ul style="list-style-type: none"> - non-interventional studies - Anticipating reimbursment issues - US-EU Regulations & safety registries <p>Off-Label Pharmacotherapy</p> <ul style="list-style-type: none"> - Off-label pharmacotherapy: when evidence without label? - Off-label Rx: cheap evidence, payers perspective? - Off-label-comparator through the eyes of FDA and EMEA 	<p>Pharmaceutical Crisis Management</p> <p>Failures in Phase III</p> <ul style="list-style-type: none"> - Role of Drug Safety Monitoring Boards - Case report before marketing approval - Case report after marketing approval <p>New therapeutic modalities under way</p> <ul style="list-style-type: none"> - Conditional and accelarated approval - New NCE Oral - Poster industrial market - Breaking News 	
Afternoon clin ops program	<p>Modern Clinical Development1</p> <ul style="list-style-type: none"> - Partners in outsourcing strategy - Patient recruitment fast or careful - Quality against every price? 	<p>Modern Clinical Development 2</p> <ul style="list-style-type: none"> - State of the Art in e-Data-Capture - Battle against cost-drivers - South-East of the globe: new trial paradise 	
Evening add-on symposium	<p>Journal editor debate: three general journals</p> <ul style="list-style-type: none"> - BMJ, Lancet, NEJM vs Drug development and Industrial Practices, Pharmaceutical Development and Technology, Clinical Research and Regulatory Affairs <p>Three questions to Pharmaceutical Scientific World</p> <ul style="list-style-type: none"> - by 1. WHO and 2. United Nations, and three answers by 2 Chief Medical Officers of top 5 Pharma Companies 		